.jpg "Cambrex Corp (NYSE: CBM)")
Yesterday, the President & CEO of Cambrex Corp (NYSE: CBM), Steven Klosk, bought shares of CBM for $685.3K.
This recent transaction increases Steven Klosk’s holding in the company by 33.67% to a total of $7.57 million.
See today’s analyst top recommended stocks >>
Based on Cambrex Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $141 million and quarterly net profit of $24.06 million. In comparison, last year the company earned revenue of $105 million and had a net profit of $19.87 million. CBM’s market cap is $1.53B and the company has a P/E ratio of 14.53. Currently, Cambrex Corp has an average volume of 446.9K.
Starting in August 2013, CBM received 7 Buy ratings in a row. Five different firms, including Craig-Hallum and Jefferies, currently also have a Buy rating on the stock.
The insider sentiment on Cambrex Corp has been negative according to 21 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies.
